Improvement in endothelium dysfunction in diabetics treated with statins: A randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg

Journal of Interventional Cardiology

Volumn 20, Issue 6, 2007, Pages 481-487

  Brunetti, Natale Daniele ^a   Maulucci, Guglielmo ^a   Casavecchia, Grazia Pia ^a   Distaso, Carlo ^a   De Gennaro, Luisa ^a   Luigi Pellegrino, Pier ^a   Di Biase, Matteo ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; FOREARM BLOOD FLOW; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; REGIONAL BLOOD FLOW; SULFONAMIDES; VASODILATION;

EID: 36549075062     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00293.x     Document Type: Article

References (41)

1. Witte DR, Westerink J, de Koning EJ, et al. Is the association between flow-mediated dilation and cardiovascular risk limited to low-risk populations? J Am Coll Cardiol 2005 45 : 1987 1993.
2. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in diabetes. Br J Pharmacol 2000 130 : 963 974.
3. Makimattila S, Yki-Jarvinen H. Endothelial dysfunction in human diabetes. Curr Diab Rep 2002 2 : 26 36.
4. Landmesser U, Hornig B, Drexler H. Endothelial function: A critical determinant in atherosclerosis? Circulation 2004 109 (21 Suppl 1 II27 II33.
5. Zhang X, Zhao SP, Li XP, et al. Endothelium-dependent and -independent functions are impaired in patients with coronary heart disease. Atherosclerosis 2000 149 : 19 24.
6. Gonzalez MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003 115 (Suppl 8A 99S 106S.
7. Poredos P, Kek Ljubec A, Poredos P, et al. Endothelial dysfunction predictor of structural changes of arterial wall in type I diabetes. Int Angiol 2006 25 : 280 286.
8. van Venrooij FV, van de Ree MA, Bots ML, et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: The Diabetes Atorvastatin Lipid Intervention (DALI) Study: A randomized, double-blind, placebo-controlled trial. Diabetes Care 2002 25 : 1211 1216.
9. Puddu P, Puddu GM, Cravero E, et al. Different effects of antihypertensive drugs on endothelial dysfunction. Acta Cardiol 2004 59 : 555 564.
10. O'Driscoll G, Green D, Maiorana A, et al. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999 33 : 1506 1511.
11. Cheetham C, Collis J, O'Driscoll G, et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000 36 : 1461 1466.
12. Tan KC, Chow WS, Tam SC, et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002 87 : 563 568.
13. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 28 : 88 136.
14. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002 39 : 257 265.
15. Caballero AE. Endothelial dysfunction, inflammation, and insulin resistance: A focus on subjects at risk for type 2 diabetes. Curr Diab Rep 2004 4 : 237 246.
16. Koltai MZ, Hadhazy P, Posa I, et al. Characteristics of coronary endothelial dysfunction in experimental diabetes. Cardiovasc Res 1997 34 : 157 163.
17. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001 37 : 1344 1350.
18. Vlachopoulos C, Aznaouridis K, Dagre A, et al. Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. Eur Heart J 2007 Jun 27 [Epub ahead of print].
19. Duman D, Sahin S, Esertas K, et al. Simvastatin improves endothelial function in patents with subclinical hypothyroidism. Heart Vessels 2007 Mar 22 (2 88 93. Epub 2007 Mar 23.
20. Schafer A, Fraccarollo D, Vogt C, et al. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Biochem Pharmacol 2007 73 : 1367 1375. Epub 2007 Jan 10.
21. Mullen MJ, Wright D, Donald AE, et al. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: A double-blind study. J Am Coll Cardiol 2000 36 : 410 416.
22. Dogra GK, Watts GF, Chan DC, et al. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. Diabet Med 2005 22 : 239 242.
23. Taneva E, Borucki K, Wiens L, et al. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol 2006 97 : 1002 1006. Epub 2006 Feb 13.
24. Dupuis J, Tardif JC, Rouleau JL, et al. Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). Am J Cardiol 2005 96 : 1207 1213. Epub 2005 Sep 6.
25. Economides PA, Caselli A, Tiani E, et al. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 2004 89 : 740 747.
26. Dupuis J, Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999 99 : 3227 3233.
27. Jensen LO, Thayssen P, Pedersen KE, et al. Effect of simvastatin on coronary flow reserve in patients with atherosclerosis and hypercholesterolemia: An intracoronary Doppler study. Coron Artery Dis 2006 17 : 51 56.
28. Hosokawa S, Hiasa Y, Tomokane T, et al. The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction. Clin Cardiol 2006 29 : 357 362.
29. ter Avest E, Abbink EJ, Holewijn S, et al. Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). Curr Med Res Opin 2005 21 : 1469 1476.
30. van de Ree MA, Huisman MV, de Man FH, et al. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 2001 52 : 299 305.
31. Tesfamariam B. The effects of HMG-CoA reductase inhibitors on endothelial function. Am J Cardiovasc Drugs 2006 6 : 115 120.
32. Vecchione C, Gentile MT, Aretini A, et al. A novel mechanism of action for statins against diabetes-induced oxidative stress. Diabetologia 2007 Feb 6 [Epub ahead of print].
33. Cohen JD, Drury JH, Ostdiek J, et al. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: A mechanism for reducing clinical events? Am Heart J 2000 139 : 734 738.
34. Link A, Ayadhi T, Böhm M, et al. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006 27 : 2945 2955.
35. Martens F, Rabelink TJ, 't Roodt J, et al. TNF-induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR- agonist pioglitazone. Eur Heart J 2006 27 : 1605 1609.
36. Shimada K, Park K, Daida H. T helper 1/T helper 2 balance and HMG-CoA reductase inhibitors in acute coronary syndrome: Statins as immunomodulatory agents? Eur Heart J 2006 27 : 2916 2918.
37. Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia - Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials 2006 7 : 35.
38. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003 92 : 152 160.
39. Berne C, Siewert-Delle A, URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol 2005 4 : 7.
40. Stender S, Schuster H, Barter P, et al. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab 2005 7 : 430 438.
41. Berry DA, Berry SM, McKellar J, et al. Comparison of the dose-response relationships of 2 lipid-lowering agents: A Bayesian meta-analysis. Am Heart J 2003 145 : 1036 1045.